[Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Noda K, Tanaka K, Ozaki M, Hirabayasi K, Hasegawa K, Nishiya I, Yakushiji M, Izumi R, Tomoda Y, Ogita Y, Sugimori H, Yamabe T, Kudo R, Yajima A, Terashima Y, Fujii S, Suzuoki Y, Okada H, Kono I, Ochiai K, Yamamoto T, Ikeda M, Umesaki N, Saito T, Niitani H, et al.
Noda K, et al. Among authors: ochiai k.
Gan To Kagaku Ryoho. 1998 Nov;25(13):2061-8.
Gan To Kagaku Ryoho. 1998.
PMID: 9838908
Clinical Trial.
Japanese.